- Report
- June 2022
- 215 Pages
United States
From €2590EUR$2,699USD£2,239GBP
- Report
- June 2021
- 195 Pages
United States
From €2399EUR$2,500USD£2,074GBP
- Report
- October 2019
- 310 Pages
Global
From €3310EUR$3,450USD£2,862GBP
- Report
- June 2019
- 220 Pages
Global
From €2101EUR$2,190USD£1,817GBP
Varivax is a vaccine used to prevent chickenpox. It is a live attenuated virus vaccine, meaning it contains a weakened form of the virus. It is administered as a single dose to children aged 12 months and older, and to adults who have never had chickenpox. The vaccine is given as an injection into the upper arm or thigh.
Varivax is a widely used vaccine, with millions of doses administered each year. It is recommended by the Centers for Disease Control and Prevention (CDC) as part of the routine childhood immunization schedule. It is also recommended for adults who have never had chickenpox.
The Varivax market is composed of pharmaceutical companies that manufacture and distribute the vaccine. These companies include Merck & Co., Inc., GlaxoSmithKline, Sanofi Pasteur, and Pfizer, Inc. Show Less Read more